May 26, 2026 – Henlius (2696.HK) announces that the first patient has been dosed in China in a randomized, double‑blind, multicenter, parallel‑controlled Phase II/III clinical study of the company’s self‑developed recombinant anti‑EGFR monoclonal antibody pimurutamab (HLX07) in combination with anti‑PD‑1…
INDIANAPOLIS, May 25, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol (LDL-C) following…
On March 9, 2026, Tenacia and Rapport Therapeutics announced an exclusive licensing agreement under which Tenacia obtained exclusive rights to develop and commercialize Rapport’s RAP‑219 in Greater China, in a deal worth up to $328 million. Under the terms of…